Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Fluticasone Propionate (skin)

Clinical medicine profile

Fluticasone Propionate (skin)

Corticosteroid

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use.

Precautions

  • Limit use in children or on face to maximum of 5 days.
  • It should be withdrawn gradually following prolonged therapy.
  • Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Fluid retention/hypertension — care in renal disease.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Prednisone needs hepatic activation to prednisolone.

03 Clinical use

Use, effects & interactions

Indications

  • Relief of some inflammatory conditions when potentially less harmful measures are ineffective Clinical selection for Fluticasone Propionate (skin) should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Corticosteroid.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension.
  • State indication and planned duration on every prescription.
  • Bone protection if prolonged.
  • Screen for strongyloides risk before prolonged high-dose in endemic exposure.
  • ICS: spacer + rinse mouth.
04 Pharmacology

Mechanism & disposition

It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors.

It diffuses across cell membranes and form…These complexes then enter the cell nucleu…Messenger RNA leads to protein synthesis o…
Read complete mechanism

It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA [mRNA]. Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids. Betamethasone may suppress transcription of mRNA in some cells like lymphocytes.

Onset

Hours–days

Duration

Agent and route dependent

Route

ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Used when maternal benefit clear; prefer agents with better obstetric data (e.g. prednisolone). Document risk–benefit.

Lactation

Low-dose systemic often compatible; time feeds if high dose — agent-specific.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Corticosteroid)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.